Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Ema entities : Abbvie inc. save search
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease
Published: 2022-07-27 (Crawled : 13:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -1.09%
H: 1.34%
C: 1.1%
rinvoq fda disease ema
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
Published: 2022-07-18 (Crawled : 07:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
treatment ema application migraine authorization
Hematological Malignancies Emerging Therapeutics - A Global Industry Assessment with Insights & Projections by Therapeutic Type, Potential Pipeline Products, Indication, and Region, 2021-2031
Published: 2022-03-16 (Crawled : 14:30) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -0.46%
H: 3.49%
C: 3.49%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 2.07%
H: 1.62%
C: 1.56%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.26%
H: 0.31%
C: -0.39%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.4%
H: 0.2%
C: -0.29%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: -1.19%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: -0.37%
ema therapeutics potential
Hematological Malignancies Drugs Market worth $ 42.78 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-08 (Crawled : 11:00) - prnewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: -0.14%
H: 5.36%
C: 5.36%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -2.75%
H: 0.28%
C: -1.04%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.38%
H: 1.81%
C: 0.28%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -1.55%
H: 0.71%
C: -0.28%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 1.4%
H: 0.7%
C: -1.15%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -0.3%
H: 3.38%
C: 0.32%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
ema drug report
Female Infertility Drugs Market to Grow by USD 538.69 mn | AbbVie Inc. and Aurobindo Pharma Ltd. Among Key Vendors | Technavio
Published: 2021-12-14 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.5%
C: -0.43%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
ema drug pharma
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
Published: 2021-11-30 (Crawled : 13:30) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
ema europe application disease risankizumab
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2021-09-16 (Crawled : 13:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.44%
H: 0.47%
C: -0.15%
treatment fda ema ulcerative colitis
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
Published: 2021-04-07 (Crawled : 13:15) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.14%
H: 0.57%
C: -0.3%
fda risankizumab ema application
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.